Hypersomnia

·MeSH: Disorders of Excessive Somnolence

11 drugs in development·7 companies·1 clinical trial

Drug Pipeline by Phase

Approved(1)

Drug	Company
LUMRYZ	Alkermes plc. (ALKS) Analyze with AI →

Phase 3(7)

Drug	Company
ALKS 2680	Alkermes plc. (ALKS) Analyze with AI →
FT218	AVADEL PHARMACEUTICALS PLC (AVDL) Analyze with AI →
hbs-301	Harmony Biosciences Holdings, Inc. (HRMY) Analyze with AI →
hbs-301	IGM Biosciences, Inc. (IGMS) Analyze with AI →
kp1077	ZEVRA THERAPEUTICS, INC. (ZVRA) Analyze with AI →
tak-360	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Analyze with AI →
tak-360	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Analyze with AI →

Phase 2(1)

Drug	Company
serdexmethylphenidate	ZEVRA THERAPEUTICS, INC. (ZVRA) Analyze with AI →

Phase 2/Phase 3(2)

Drug	Company
Alixorexton (ALKS 2680)	Alkermes plc. (ALKS) Analyze with AI →
tak-360	TAKEDA PHARMACEUTICAL CO LTD (TKPHF) Analyze with AI →

BioSniper tracks 11 drugs in development for Hypersomnia across 7 companies.

There are 1 clinical trial targeting Hypersomnia tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.